trial · primary record
Surabgene Lomparvovec (ABBV-RGX-314)
Neovascular Age-related Macular Degeneration
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 561 |
| Primary completion | 2033-03 |
| Primary endpoint | Annualized intravitreal anti-VEGF injection rate |
| Registry ID | NCT07007065 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:29.223Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07007065
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.